# **Original article**

# Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis

Wei-jie Guan<sup>1,#</sup>, Ph.D., Wen-hua Liang<sup>2,#</sup>, M.D., Yi Zhao<sup>2,#</sup>, M.Med., Heng-rui Liang<sup>2,#</sup>, M.Med., Zi-sheng Chen<sup>2,3,#</sup>, M.D., Yi-min Li <sup>4</sup>, M.D., Xiao-qing Liu <sup>4</sup>, M.D., Ru-chong Chen <sup>1</sup>, M.D., Chun-li Tang <sup>1</sup>, M.D., Tao Wang <sup>1</sup>, M.D., Chun-quan Ou <sup>5</sup>, Ph.D., Li Li <sup>5</sup>, Ph.D., Ping-yan Chen <sup>5</sup>, M.D., Ling Sang <sup>4</sup>, M.D., Wei Wang <sup>2</sup>, M.D., Jian-fu Li <sup>2</sup>, M.D., Cai-chen Li <sup>2</sup>, M.D., Li-min Ou <sup>2</sup>, M.D., Bo Cheng <sup>2</sup>, M.D., Shan Xiong <sup>2</sup>, M.D., Zheng-yi Ni <sup>6</sup>, M.D., Jie Xiang <sup>6</sup>, M.D., Yu Hu <sup>7</sup>, M.D., Lei Liu <sup>8,9</sup>, M.D., Hong Shan <sup>10</sup>, M.D., Chun-liang Lei <sup>11</sup>, M.D., Yi-xiang Peng <sup>12</sup>, M.D., Li Wei <sup>13</sup>, M.D., Yong Liu <sup>14</sup>, M.D., Ya-hua Hu <sup>15</sup>, M.D., Peng Peng <sup>16</sup>, M.D., Jian-ming Wang <sup>17</sup>, M.D., Ji-yang Liu <sup>18</sup>, M.D., Zhong Chen <sup>19</sup>, M.D., Gang Li <sup>20</sup>, M.D., Zhi-jian Zheng <sup>21</sup>, M.D., Shao-qin Qiu <sup>22</sup>, M.D., Jie Luo <sup>23</sup>, M.D., Chang-jiang Ye <sup>24</sup>, M.D., Shao-yong Zhu <sup>25</sup>, M.D., Lin-ling Cheng <sup>1</sup>, M.D., Feng Ye <sup>1</sup>, M.D., Shi-yue Li <sup>1</sup>, M.D., Jin-ping Zheng <sup>1</sup>, M.D., Nuo-fu Zhang <sup>1</sup>, M.D., Nan-shan Zhong <sup>1,\*</sup>, M.D., Jian-xing He <sup>2,\*</sup>, M.D., on behalf of China Medical Treatment Expert Group for COVID-19

<sup>&</sup>lt;sup>1</sup> State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

<sup>&</sup>lt;sup>2</sup> Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

<sup>&</sup>lt;sup>3</sup> The sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, Guangdong, China

<sup>&</sup>lt;sup>4</sup> Department of Pulmonary and Critical Care Medicine, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

<sup>&</sup>lt;sup>5</sup> State Key Laboratory of Organ Failure Research, Department of Biostatistics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China

<sup>&</sup>lt;sup>6</sup> Wuhan Jin-yintan Hospital, Wuhan, Hubei, China

<sup>&</sup>lt;sup>7</sup> Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China

<sup>&</sup>lt;sup>8</sup> Shenzhen Third People's Hospital, Shenzhen, China

<sup>&</sup>lt;sup>9</sup> The Second Affiliated Hospital of Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China

<sup>&</sup>lt;sup>10</sup> The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China

<sup>&</sup>lt;sup>11</sup> Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China

<sup>&</sup>lt;sup>12</sup> The Central Hospital of Wuhan, Wuhan, Hubei, China

<sup>&</sup>lt;sup>13</sup> Wuhan No.1 Hospital, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, Hubei, China

<sup>&</sup>lt;sup>14</sup> Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan, China

<sup>&</sup>lt;sup>15</sup> Huangshi Central Hospital of Edong Healthcare Group, Affiliated Hospital of Hubei Polytechnic University, Huangshi, Hubei, China

<sup>&</sup>lt;sup>16</sup> Wuhan Pulmonary Hospital, Wuhan, 430030, Hubei, China

 $<sup>^{\</sup>rm 17}$  Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430065, China

<sup>&</sup>lt;sup>18</sup> The First Hospital of Changsha, Changsha 410005, Hunan, China

<sup>&</sup>lt;sup>19</sup> The Third People's Hospital of Hainan Province, Sanya, 572000, Hainan, China

<sup>&</sup>lt;sup>20</sup> Huanggang Central Hospital, Huanggang, Hubei, China

<sup>&</sup>lt;sup>21</sup> Wenling First People's Hospital, Wenling, Zhejiang, China

<sup>&</sup>lt;sup>22</sup> The Third People's Hospital of Yichang, Yichang, 443000, Hubei Province, China

<sup>&</sup>lt;sup>23</sup> Affiliated Taihe Hospital of Hubei University of Medicine, Shiyan, China

<sup>&</sup>lt;sup>24</sup> Xiantao First People's Hospital, Xiantao, China

<sup>&</sup>lt;sup>25</sup> The People's Hospital of Huangpi District, Wuhan, China

<sup>&</sup>lt;sup>#</sup> Wei-jie Guan, Wen-hua Liang, Yi Zhao, Heng-rui Liang and Zi-sheng Chen are joint first authors.

Correspondence to: Jian-xing He MD, PhD, FACS, FRCS, AATS active member, ESTS member. Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University; China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China. Tel: +86-20-8337792; Fax: +86-20-83350363; Email: <a href="mailto:drjianxing.he@gmail.com">drjianxing.he@gmail.com</a>; or Nan-Shan Zhong. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou, Guangdong, China. Tel.: +86-20-83062729; Fax: +86-20-83062729; E-mail: nanshan@vip.163.com

**Conflict of interest**: There is no conflict of interest.

**Ethics approval**: This study is approved by the ethics committee of the First Affiliated Hospital of Guangzhou Medical University.

Abstract

**Objective**: To evaluate the spectrum of comorbidities and its impact on the clinical outcome in

patients with coronavirus disease 2019 (COVID-19).

**Design:** Retrospective case studies

Setting: 575 hospitals in 31 province/autonomous regions/provincial municipalities across China

Participants: 1,590 laboratory-confirmed hospitalized patients. Data were collected from November

21<sup>st</sup>, 2019 to January 31<sup>st</sup>, 2020.

Main outcomes and measures: Epidemiological and clinical variables (in particular, comorbidities)

were extracted from medical charts. The disease severity was categorized based on the American

Thoracic Society guidelines for community-acquired pneumonia. The primary endpoint was the

composite endpoints, which consisted of the admission to intensive care unit (ICU), or invasive

ventilation, or death. The risk of reaching to the composite endpoints was compared among patients

with COVID-19 according to the presence and number of comorbidities.

**Results**: Of the 1,590 cases, the mean age was 48.9 years. 686 patients (42.7%) were females. 647

(40.7%) patients were managed inside Hubei province, and 1,334 (83.9%) patients had a contact

history of Wuhan city. Severe cases accounted for 16.0% of the study population. 131 (8.2%)

patients reached to the composite endpoints. 399 (25.1%) reported having at least one comorbidity.

269 (16.9%), 59 (3.7%), 30 (1.9%), 130 (8.2%), 28 (1.8%), 24 (1.5%), 21 (1.3%), 18 (1.1%) and 3

(0.2%) patients reported having hypertension, cardiovascular diseases, cerebrovascular diseases,

diabetes, hepatitis B infections, chronic obstructive pulmonary disease, chronic kidney diseases,

4

malignancy and immunodeficiency, respectively. 130 (8.2%) patients reported having two or more

comorbidities. Patients with two or more comorbidities had significantly escalated risks of reaching

to the composite endpoint compared with those who had a single comorbidity, and even more so as

compared with those without (all P<0.05). After adjusting for age and smoking status, patients with

COPD (HR 2.681, 95%CI 1.424-5.048), diabetes (HR 1.59, 95%CI 1.03-2.45), hypertension (HR

1.58, 95%CI 1.07-2.32) and malignancy (HR 3.50, 95%CI 1.60-7.64) were more likely to reach to

the composite endpoints than those without. As compared with patients without comorbidity, the HR

(95%CI) was 1.79 (95%CI 1.16-2.77) among patients with at least one comorbidity and 2.59 (95%CI

1.61-4.17) among patients with two or more comorbidities.

Conclusion: Comorbidities are present in around one fourth of patients with COVID-19 in China,

and predispose to poorer clinical outcomes.

**FUNDING:** Supported by National Health Commission, Department of Science and Technology of

Guangdong Province. The funder had no role in the conduct of the study.

5

**Key words:** SARS-CoV-2; comorbidity; clinical characteristics; prognosis

Main text: 2,354 words; abstract: 365 words

**Short title**: Comorbidity of COVID-19 in China

Author's contributions: W. J. G., W. H. L., J. X. H., and N. S. Z. participated in study design and study conception; W. H. L., Y. Z., H. R. L., Z. S. C., C. Q. O., L. L., P. Y. C., J. F. L., C. C. L., L. M. O., B. C., W. W. and S. X. performed data analysis; R. C. C., C. L. T., T. W., L. S., Z. Y. N., J. X., Y. H., L. L., H. S., C. L. L., Y. X. P., L. W., Y. L., Y. H. H., P. P., J. M. W., J. Y. L., Z. C., G. L., Z. J. Z., S. Q. Q., J. L., C. J. Y., S. Y. Z., L. L. C., F. Y., S. Y. L., J. P. Z., N. F. Z., and N. S. Z. recruited patients; W. J. G., J. X. H., W. H. L., and N. S. Z. drafted the manuscript; all authors provided critical review of the manuscript and approved the final draft for publication.

# **Highlights**

## What is already known on this topic?

- Since November 2019, the rapid outbreak of coronavirus disease 2019 (COVID-19) has recently become a public health emergency of international concern. There have been 79,331 laboratory-confirmed cases and 2,595 deaths globally as of February 25<sup>th</sup>, 2020
- Previous studies have demonstrated the association between comorbidities and other severe acute respiratory diseases including SARS and MERS.
- No study with a nationwide representative cohort has demonstrated the spectrum of comorbidities and the impact of comorbidities on the clinical outcomes in patients with COVID-19.

## What this study adds?

- In this nationwide study with 1,590 patients with COVID-19, comorbidities were identified in 399

patients. Comorbidities of COVID-19 mainly included hypertension, cardiovascular diseases,

cerebrovascular diseases, diabetes, hepatitis B infections, chronic obstructive pulmonary disease,

chronic kidney diseases, malignancy and immunodeficiency.

- The presence of as well as the number of comorbidities predicted the poor clinical outcomes

(admission to intensive care unit, invasive ventilation, or death) of COVID-19.

- Comorbidities should be taken into account when estimating the clinical outcomes of patients with

COVID-19 on hospital admission.

Introduction

Since November 2019, the rapid outbreak of coronavirus disease 2019 (COVID-19), which arose

from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has recently become

a public health emergency of international concern [1]. COVID-19 has contributed to an enormous

adverse impact globally. Hitherto, there have been 79,331 laboratory-confirmed cases and 2,595

deaths globally as of February 25<sup>th</sup>, 2020 [2].

The clinical manifestations of COVID-19 are, according to the latest reports [3-8], largely

heterogeneous. On admission, 20-51% of patients reported as having at least one comorbidity, with

diabetes (10-20%), hypertension (10-15%) and cardiovascular and cerebrovascular diseases (7-40%)

being most common [3,4,6]. Previous studies have demonstrated that the presence of any

comorbidity has been associated with a 3.4-fold increased risk of developing acute respiratory

distress syndrome in patients with H7N9 infection [9]. Similar with influenza [10-14], Severe Acute

7

Respiratory Syndrome coronavirus (SARS-CoV) [15] and Middle East Respiratory Syndrome

coronavirus (MERS-CoV) [16-24], COVID-19 more readily predisposed to respiratory failure and

death in susceptible patients [4]. Nonetheless, previous studies have been certain limitations in study

design including the relatively small sample sizes and single center observations. Studies that address

these limitations is needed to explore for the factors underlying the adverse impact of COVID-19.

Our objective was to compare the clinical characteristics and outcomes of patients with

COVID-19 by stratification according to the presence and category of comorbidity, thus unraveling

the subpopulations with poorer prognosis.

Methods

Data sources and data extraction

This was a retrospective cohort study that collected data from patients with COVID-19 throughout

China, under the coordination of the National Health Commission which mandated the reporting of

clinical information from individual designated hospitals which admitted patients with COVID-19.

After careful medical chart review, we compiled the clinical data of laboratory-confirmed

hospitalized cases from 575 hospitals between November 21st, 2019 and January 31st, 2020. The

diagnosis of COVID-19 was made based on the World Health Organization interim guidance [25].

Confirmed cases denoted the patients whose high-throughput sequencing or real-time

reverse-transcription polymerase-chain-reaction (RT-PCR) assay findings for nasal and pharyngeal

8

swab specimens were positive [3]. See *Online Supplement* for details.

The clinical data (including recent exposure history, clinical symptoms and signs, comorbidities,

and laboratory findings upon admission) were reviewed and extracted by experienced respiratory

clinicians, who subsequently entered the data into a computerized database for further

cross-checking. Manifestations on chest X-ray or computed tomography (CT) was summarized by

integrating the documentation or description in medical charts and, if available, a further review by

our medical staff. Major disagreement of the radiologic manifestations between the two reviewers

was resolved by consultation with another independent reviewer. Because disease severity reportedly

predicted poorer clinical outcomes of avian influenza [9], patients were classified as having severe or

non-severe COVID-19 based on the American Thoracic Society guidelines for community-acquired

pneumonia because of its global acceptance [26].

Comorbidities were determined based on patient's self-report on admission. Comorbidities were

initially treated as a categorical variable (Yes vs. No), and subsequently classified based on the

number (Single vs. Multiple). Furthermore, comorbidities were sorted according to the organ

systems (i.e. respiratory, cardiovascular, endocrine). Comorbidities that were classified into the same

organ system (i.e. coronary heart disease, hypertension) would be merged into a single category.

The primary endpoint of our study was a composite measure which consisted of the admission

to intensive care unit (ICU), or invasive ventilation, or death. This composite measure was adopted

because all individual components were serious outcomes of H7N9 infections [9]. Secondary

endpoints mainly included the mortality rate, and the time from symptom onset to reaching to the

9

composite endpoints.

Statistical analysis

Statistical analyses were conducted with SPSS software version 23.0 (Chicago, IL, USA). No formal

sample size estimation was made because there has not been any published nationwide data on

COVID-19. Nonetheless, our sample size was deemed sufficient to power the statistical analysis

given its representativeness of the national patient population. Continuous variables were presented

as means and standard deviations or medians and interquartile ranges (IQR) as appropriate, and the

categorical variables were presented as counts and percentages. Independent t-test, Kruskal-Wallis

test and chi-square test were applied for the comparisons between the two groups as appropriate. Cox

proportional hazard regression models were applied to determine the potential risk factors associated

with the composite endpoints, with the hazards ratio (HR) and 95% confidence interval (95%CI)

being reported.

Patient and public involvement

No patients were directly involved in our study design, setting the research questions, the

interpretation of data, or asked to advise on writing up of the report.

**Results** 

Demographic and clinical characteristics

The National Health Commission has issued 11,791 patients with laboratory-confirmed COVID-19

in China as of January 31st, 2020. At this time point for data cut-off, our database has included 1,590

cases from 575 hospitals in 31 province/autonomous regions/provincial municipalities (see Online

Supplement for details). Of these 1,590 cases, the mean age was 48.9 years. 686 patients (42.7%)

10

were females. 647 (40.7%) patients were managed inside Hubei province, and 1,334 (83.9%) patients had a contact history of Wuhan city. The most common symptom was fever on or after hospitalization (88.0%), followed by dry cough (70.2%). Fatigue (42.8%) and productive cough (36.0%) were less common. At least one abnormal chest CT manifestation (including ground-glass opacities, pulmonary infiltrates and interstitial disorders) was identified in more than 70% of patients. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached to the composite endpoints during the study (**Table 1**).

Presence of comorbidities and the clinical characteristics and outcomes of COVID-19

Of the 1,590 cases, 399 (25.1%) reported having at least one comorbidity. The most common comorbidities encompassed hypertension (269 [16.9%]), diabetes (130 [8.2%]), and cardiovascular diseases (59 [3.7%]). Chronic obstructive pulmonary disease (COPD) was identified in 24 cases. At least one comorbidity was seen more commonly in severe cases than in non-severe cases (32.8% vs. 10.3%). Patients with at least one comorbidity were older (mean: 60.8 vs. 44.8 years), were more likely to have shortness of breath (41.4% vs. 17.8%), nausea or vomiting (10.4% vs. 4.3%), and tended to have abnormal chest X-ray manifestations (29.2% vs. 15.1%) (**Table 1**).

Clinical characteristics and outcomes of COVID-19 stratified by the number of comorbidities

We have further identified 130 (8.2%) patients who reported having two or more comorbidities. Two or more comorbidities were more commonly seen in severe cases than in non-severe cases (40.0% vs. 29.4%, P<0.001). Patients with two or more comorbidities were older (mean: 66.2 vs. 58.2 years), were more likely to have shortness of breath (55.4% vs. 34.1%), nausea or vomiting (11.8% vs. 9.7%), unconsciousness (5.1% vs. 1.3%) and less abnormal chest X-ray (20.8% vs. 23.4%) compared

with patients who had single comorbidity (**Table 2**).

Clinical characteristics and outcomes of COVID-19 stratified by organ systems of comorbidities

A total of 269 (16.9%), 59 (3.7%), 30 (1.9%), 130 (8.2%), 28 (1.8%), 24 (1.5%), 21 (1.3%), 18

(1.1%) and 3 (0.2%) patients reported having hypertension, cardiovascular diseases, cerebrovascular

diseases, diabetes, hepatitis B infections, COPD, chronic kidney diseases, malignancy and

immunodeficiency, respectively. Severe cases were more likely to have hypertension (32.7% vs.

12.6%), cardiovascular diseases (33.9% vs. 15.3%), cerebrovascular diseases (50.0% vs. 15.3%),

diabetes (34.6% vs. 14.3%), hepatitis B infections (32.1% vs. 15.7%), COPD (62.5% vs. 15.3%),

chronic kidney diseases (38.1% vs. 15.7%) and malignancy (50.0% vs. 15.6%) compared with

non-severe cases. Furthermore, comorbidities were more common patients treated in Hubei province

as compared with those managed outside Hubei province (all P<0.05) as well as patients with an

exposure history of Wuhan as compared with those without (all P<0.05) (**Table 3**).

Prognostic analyses

The composite endpoint was documented in 77 (19.3%) of patients who had at least one comorbidity

as opposed to 54 (4.5%) patients without comorbidities (P<0.001). This figure was 37 cases (28.5%)

in patients who had two or more comorbidities. Significantly more patients with hypertension

(19.7% vs. 5.9%), cardiovascular diseases (22.0% vs. 7.7%), cerebrovascular diseases (33.3% vs.

7.8%), diabetes (23.8% vs. 6.8%), COPD (50.0% vs. 7.6%), chronic kidney diseases (28.6% vs.

8.0%) and malignancy (38.9% vs. 7.9%) reached to the composite endpoints compared with those

12

without (Table 3).

Patients with two or more comorbidities had significantly escalated risks of reaching to the composite endpoint compared with those who had a single comorbidity, and even more so as compared with those without (all *P*<0.05, **Figure 1**). After adjusting for age and smoking status, patients with COPD (HR 2.68, 95%CI 1.42-5.05), diabetes (HR 1.59, 95%CI 1.03-2.45), hypertension (HR 1.58, 95%CI 1.07-2.32) and malignancy (HR 3.50, 95%CI 1.60-7.64) were more likely to reach to the composite endpoints than those without (**Figure 2**). As compared with patients without comorbidity, the HR (95%CI) was 1.79 (95%CI 1.16-2.77) among patients with at least one comorbidity and 2.59 (95%CI 1.61-4.17) among patients with two or more comorbidities (**Figure 2**).

#### **Discussion**

Our study is the first nationwide investigation that systematically evaluates the impact of comorbidities on the clinical characteristics and prognosis in patients with COVID-19 in China. Circulatory and endocrine comorbidities were common among patients with COVID-19. Patients with at least one comorbidity, or more even so, were associated with poor clinical outcomes. These findings have provided further objective evidence, with a large sample size and extensive coverage of the geographic regions across China, to take into account baseline comorbid diseases in the comprehensive risk assessment of prognosis among patients with COVID-19 on hospital admission.

Overall, our findings have echoed the recently published studies in terms of the commonness of comorbidities in patients with COVID-19 [3-7]. Despite considerable variations in the proportion in individual studies due to the limited sample size and the region where patients were managed, circulatory diseases (including hypertension and coronary heart diseases) remained the most

common category of comorbidity [3-7]. Apart from circulatory diseases, endocrine diseases such as diabetes were also common in patients with COVID-19. Notwithstanding the commonness of circulatory and endocrine comorbidities, patients with COVID-19 rarely reported as having comorbid respiratory diseases (particularly COPD). The reasons underlying this observation have been scant, but could have arisen from the lack of awareness and the lack of spirometric testing in community settings that collectively contributed to the underdiagnosis of respiratory diseases [27]. Consistent with recent reports [3-7], the percentage of patients with comorbid renal disease and malignancy was relatively low. Our findings have therefore added to the existing literature the spectrum of comorbidities in patients with COVID-19 based on the larger sample sizes and representativeness of the whole patient population in China.

A number of existing literature reports have documented the escalated risks of poorer clinical outcomes in patients with avian influenza [10-14], SARS-CoV [15] and MERS-CoV infections [16-24]. The most common comorbidities associated with poorer prognosis included diabetes [21,24], hypertension [24], respiratory diseases [15,24], cardiac diseases [15,24], pregnancy [12], renal diseases [24] and malignancy [15]. Our findings suggested that, similar with other severe acute respiratory outbreaks, comorbidities such as COPD, diabetes, hypertension and malignancy predisposed to adverse clinical outcomes in patients with COVID-19. The strength of association between different comorbidities and the prognosis, however, was less consistent when compared with the literature reports [12,15,21,24]. For instance, the risk between cardiac diseases and poor clinical outcomes of influenza, SARS-CoV or MERS-CoV infections was inconclusive [12,15,21,24]. Except for diabetes, no other comorbidities were identified to be the predictors of poor clinical outcomes in patients with MERS-CoV infections [21]. Few studies, however, have explored the

mechanisms underlying these associations. Kulscar et al showed that MERS-CoV infections resulted in prolonged airway inflammation, immune cell dysfunction and an altered expression profile of inflammatory mediators [23]. A network-based analysis indicated that SARS-CoV infections led to immune dysregulation that could help explain the escalated risk of cardiac diseases, bone diseases and malignancy [28]. Therefore, immune dysregulation and prolonged inflammation might be the key drivers of the poor clinical outcomes in patients with COVID-19 but await verification in more mechanistic studies.

There has been a considerable overlap in the comorbidities which has been widely accepted. For instance, diabetes [29] and COPD [30] frequently co-exist with hypertension or coronary heart diseases. Therefore, patients with co-existing comorbidities are more likely to have poorer baseline well-being. Importantly, we have verified the significantly escalated risk of poor prognosis in patients with two or more comorbidities as compared with those who had no or only a single comorbidity. Our findings implied that both the category and number of comorbidities should be taken into account when predicting the prognosis in patients with COVID-19.

Our findings suggested that patients with comorbidities had greater disease severity compared with those without. A greater number of comorbidities correlated with greater disease severity of COVID-19. The public health implication of our study was that proper triage of patients should be implemented in out-patient clinics or on hospital admission by carefully inquiring the medical history because this will help identify patients who would be more likely to develop serious adverse outcomes during the progression of COVID-19. A multidisciplinary team with specialists would be needed to manage the comorbid conditions in a timely fashion. Moreover, patients with COIVD-19

15

who had comorbidities should be isolated immediately upon confirmation of the diagnosis, which

would help provide with this susceptible population better personal medical protection.

The main limitation of our study was the self-report of comorbidities on admission.

Underreporting of comorbidities, which could have stemmed from the lack of awareness and/or the

lack of diagnostic testing, might contribute to the underestimation of the true strength of association

with the clinical prognosis. However, significant underreporting was unlikely because the spectrum

of our report was largely consistent with existing literature [3-7] and all patients were subject to a

thorough history taking after hospital admission. Moreover, the duration of follow-up was relatively

short and some patients remained in the hospital as of the time of writing. More studies that explore

the associations in a sufficiently long time frame are warranted. As with other observational studies,

our findings did not provide direct inference about the causation or reverse causation of

comorbidities and the poor clinical outcomes.

**Conclusions** 

Comorbidities are present in around one fourth of patients with COVID-19 in China, and predispose

to poorer clinical outcomes. A thorough assessment of comorbidities may help establish risk

16

stratification of patients with COVID-19 upon hospital admission.

**Acknowledgment**: We thank the hospital staff (see Supplementary Appendix for the full list) for

their efforts in collecting the information. We are indebted to the coordination of Drs. Zong-jiu Zhang, Ya-hui Jiao, Bin Du, Xin-qiang Gao and Tao Wei (National Health Commission), Yu-fei Duan and Zhi-ling Zhao (Health Commission of Guangdong Province), Yi-min Li, Zi-jing Liang, Nuo-fu Zhang, Shi-yue Li, Qing-hui Huang, Wen-xi Huang and Ming Li (Guangzhou Institute of Respiratory Health) which greatly facilitate the collection of patient's data. Special thanks are given to the statistical team members Prof. Zheng Chen, Drs. Dong Han, Li Li, Zheng Chen, Zhi-ying Zhan, Jin-jian Chen, Li-jun Xu, Xiao-han Xu (State Key Laboratory of Organ Failure Research, Department of Biostatistics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University). We also thank Li-qiang Wang, Wei-peng Cai, Zi-sheng Chen (the sixth affiliated hospital of Guangzhou medical university), Chang-xing Ou, Xiao-min Peng, Si-ni Cui, Yuan Wang, Mou Zeng, Xin Hao, Qi-hua He, Jing-pei Li, Xu-kai Li, Wei Wang, Li-min Ou, Ya-lei Zhang, Jing-wei Liu, Xin-guo Xiong, Wei-juna Shi, San-mei Yu, Run-dong Oin, Si-yang Yao, Bo-meng Zhang, Xiao-hong Xie, Zhan-hong Xie, Wan-di Wang, Xiao-xian Zhang, Hui-yin Xu, Zi-qing Zhou, Ying Jiang, Ni Liu, Jing-jing Yuan, Zheng Zhu, Jie-xia Zhang, Hong-hao Li, Wei-hua Huang, Lu-lin Wang, Jie-ying Li, Li-fen Gao, Jia-bo Gao, Cai-chen Li, Xue-wei Chen, Jia-bo Gao, Ming-shan Xue, Shou-xie Huang, Jia-man Tang, Wei-li Gu, Jin-lin Wang (Guangzhou Institute of Respiratory Health) for their dedication to data entry and verification. We are grateful to Tecent Co. Ltd. for their provision of the number of certified hospitals for admission of patients with COVID-19 throughout China. Finally, we thank all the patients who consented to donate their data for analysis and the medical staffs working in the front line.

#### **Statements**

All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi\_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all worldwide licence authors, (http://www.bmj.com/sites/default/files/BMJ%20Author%20Licence%20March%202013.doc) to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution and convert or allow conversion into any format including without limitation audio, iii) create any other derivative work(s) based in whole or part on the on the Contribution, iv) to exploit all subsidiary rights to exploit all subsidiary rights that currently exist or as may exist in the future in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above. All research articles will be made available on basis (with authors being asked an access open access fee—seehttp://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-o pen-access-and-permission-reuse). The terms of such open access shall be governed by a Creative

Commons licence—details as to which Creative Commons licence will apply to the research article are set out in our worldwide licence referred to above.

### Reference

- 1. WHO main website. https://www.who.int (accessed February 25<sup>th</sup>, 2020)
- 2. World Health Organization. Novel Coronavirus (2019-nCoV) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ (Assessed on February 25<sup>th</sup>, 2020)
- 3. Huang C, Wang Y, Li X, et al. Clinical features of patients with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020; doi: 10.1016/S0140-6736(20)30183-5
- 4. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020. doi: 10.1016/S0140-6736(20)30211-7
- 5. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020 Feb 7. doi: 10.1001/jama.2020.1585
- 6. Kui L, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J (Engl)*. 2020 Feb 7. doi: 10.1097/CM9.00000000000000744

- 7. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case studies. *BMJ*. 2020; 368:m606
- 8. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet*. 2020; doi: 10.1016/S0140-6736(20)30154-9
- 9. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection.

  N Engl J Med. 2013; 368:2277-85
- 10. Placzek HED, Madoff LC. Association of age and comorbidity on 2009 influenza A pandemic H1N1-related intensive care unit stay in Massachusetts. *Am J Public Health*. 2014;104:e118-e125
- 11. Mauskopf J, Klesse M, Lee S, Herrera-Taracena G. The burden of influenza complications in different high-risk groups. *J Med Economics*. 2013;16:264-77
- 12. Shiley KT, Nadolski G, Mickus T, et al. Differences in the epidemiological characteristics and clinical outcomes of pandemic (H1N1) 2009 influenza, compared with seasonal influenza. *Infect Control Hosp Epidemiol*. 2010; 31: 676–682
- 13. Martinez A, Soldevila N, Romeo-Tamarit A, et al. Risk factors associated with severe outcomes in adult hospitalized patients according to influenza type and subtype. *Plos One*. 2019;14:e0210353
- 14. Gutiérrez-González E, Cantero-Escribano JM, Redondo-Bravo L, et al. Effect of vaccination, comorbidities and age on mortality and severe disease associated with influenza during the season 2016–2017 in a Spanish tertiary hospital. *J Infect Public Health*. 2019;12:486-491

- 15. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. *JAMA*. 2003;289:2801-2809
- 16. Alqahtani FY, Aleanizy FS, Ali Hadi Mohammed R, et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. *Epidemiol Infect*. 2018;5:1-5
- 17. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV). *Int J Infect Dis.* 2016;49:129-133
- 18. Rahman A, Sarkar A. Risk Factors for Fatal Middle East Respiratory Syndrome Coronavirus Infections in Saudi Arabia: Analysis of the WHO Line List, 2013-2018. *Am J Public Health*. 2019;305186
- 19. Alanazi KH, Abedi GR, Midgley CM, et al. Diabetes Mellitus, Hypertension, and Death among 32 Patients with MERS-CoV Infection, Saudi Arabia. *Emerging Infect Dis.* 2020;26:166-168
- 20. Yang YM, Hsu CY, Lai CC, et al. Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory Syndrome. *Sci Rep.* 2017;7:11307
- 21. Garbati MA, Fagbo SF, Fang VJ, et al. A Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS Coronavirus or Other Causes. *Plos One*. 2016;11:e0165978
- 22. Rivers CM, Majumder MS, Lofgren ET. Risks of Death and Severe Disease in Patients With Middle East Respiratory Syndrome Coronavirus, 2012–2015. *Am J Epidemiol*. 2016;184:460-464
- 23. Kulscar KA, Coleman CM, Beck S, Frieman MB. Comorbid diabetes results in immune

dysregulation and enhanced disease severity following MERS-CoV infection. *JCI Insight*. 2019;20:e131774

- 24. Matsuyama R, Nishiura H, Kutsuna S, et al. Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis. *BMC Public Health*. 2016;16:1203
- 25. WHO. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance. Jan 28, 2020. <a href="https://www.who.int/internal-publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected (accessed February 25<sup>th</sup>, 2020)</a>
- 26. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia: An official clinical practice guideline of the American Thoracic Society and Infectious Disease Society of America. *Am J Respir Crit Care Med*. 2019; 200:e45-e67
- 27. Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. *Lancet Respir Med*. 2018;6:421-430
- 28. Moni MA, Lionel P. Network-based analysis of comorbidities risk during an infection: SARS and HIV case studies. *BMC Bioinformatics* 2014, 15:333
- 29. Naqvi AA, Shah A, Ahmad R, Ahmad N. Developing an Integrated Treatment Pathway for a Post-Coronary Artery Bypass Grating (CABG) Geriatric Patient with Comorbid Hypertension and Type 1 Diabetes Mellitus for Treating Acute Hypoglycemia and Electrolyte Imbalance. *J Pharm Bioallied Sci.* 2017;9:216-220

30. Murphy TE, McAvay GJ, Allore HG, et al. Contributions of COPD, asthma, and ten comorbid conditions to health care utilization and patient-centered outcomes among US adults with obstructive airway disease. *Int J Chron Obstruct Pulmon Dis.* 2017;12:2515-2522

# **Tables**

Table 1: Demographics and clinical characteristics of patients with or without any comorbidities.

Variables	Any comorbidity										
	Total	No	Yes	P							
	(n=1590)	(n=1191)	(n=399)	Value							
Age (years)	48.9±16.3	44.8±15.2	60.8±13.4	<0.001							
Incubation period (day)	3.6±4.2	3.7±4.3	3.5±3.9	0.329							
Temperature on admission (□)	37.4±0.9	37.4±0.9	37.3±0.9	0.034							
Respiratory rate on admission (breath/min)	21.2±12.0	21.2±13.7	21.3±4.7	0.876							
Heart rate on admission (beat/min)	88.7±14.6	88.5±14.7	89.2±14.4	0.402							
Systolic pressure on admission (mmHg)	126.1±16.4	123.5±15.2	133.2±17.5	<0.001							
Diastolic pressure on admission (mmHg)	79.5±25.6	79±28.9	80.9±12.6	0.22							
Highest temperature (□)	38.3±1.6	38.3±1.1	38.2±2.6	0.634							
Sex				0.241							
Male	904/1578 (57.3)	667/1182 (56.4)	237/396 (59.8)								
Female	674/1578 (42.7)	515/1182 (43.6)	159/396 (40.2)								
Smoking status				<0.001							
Never/unknown	1479/1590 (93)	1127/1191 (94.6)	352/399 (88.2)								
Former/current	111/1590 (7)	64/1191 (5.4)	47/399 (11.8)								
Symptoms											
Fever	1351/1536 (88)	1002/1148 (87.3)	349/388 (89.9)	0.176							
Conjunctival congestion	10/1345 (0.7)	7/1014 (0.7)	3/331 (0.9)	0.715							
Nasal congestion	73/1299 (5.6)	59/979 (6)	14/320 (4.4)	0.328							
Headache	205/1328 (15.4)	151/1002 (15.1)	54/326 (16.6)	0.537							

Dry cough	1052/1498 (70.2)	775/1116 (69.4)	277/382 (72.5)	0.271
Pharyngodynia	194/1317 (14.7)	148/999 (14.8)	46/318 (14.5)	0.928
Productive cough	513/1424 (36)	363/1064 (34.1)	150/360 (41.7)	0.011
Fatigue	584/1365 (42.8)	435/1031 (42.2)	149/334 (44.6)	0.446
Hemoptysis	16/1315 (1.2)	9/991 (0.9)	7/324 (2.2)	0.084
Shortness of breath	331/1394 (23.7)	185/1041 (17.8)	146/353 (41.4)	<0.001
Nausea/vomiting	80/1371 (5.8)	44/1025 (4.3)	36/346 (10.4)	<0.001
Diarrhea	57/1359 (4.2)	39/1023 (3.8)	18/336 (5.4)	0.213
Myalgia/arthralgia	234/1338 (17.5)	174/1007 (17.3)	60/331 (18.1)	0.739
Chill	163/1333 (12.2)	129/1006 (12.8)	34/327 (10.4)	0.285
Signs				
Throat congestion	21/1286 (1.6)	16/973 (1.6)	5/313 (1.6)	1
Tonsil swelling	31/1376 (2.3)	22/1024 (2.1)	9/352 (2.6)	0.678
Enlargement of lymph nodes	2/1375 (0.1)	1/1027 (0.1)	1/348 (0.3)	0.442
Rash	3/1378 (0.2)	2/1032 (0.2)	1/346 (0.3)	1
Unconsciousness	20/1421 (1.4)	11/1063 (1)	9/358 (2.5)	0.064
Abnormal chest image				
Radiograph	243/1590 (15.3)	236/1566 (15.1)	44036 (29.2)	0.079
Computed tomography	1130/1590 (71.1)	1113/1566 (71.1)	17/24 (70.8)	1
Hubei				<0.001
Yes	647/1590 (40.7)	434/1191 (36.4)	213/399 (53.4)	
No	943/1590 (59.3)	757/1191 (63.6)	186/399 (46.6)	
Wuhan-contacted				0.012

No	256/1590 (16.1)	208/1191 (17.5)	48/399 (12)	
Severity	254/1590 (16)	123/1191 (10.3)	131/399 (32.8)	<0.001
Composite endpoint	131/1590 (8.2)	54/1191 (4.5)	77/399 (19.3)	<0.001
Death	50/1590 (3.1)	15/1191 (1.3)	35/399 (8.8)	<0.001

Data are mean  $\pm$  standard deviation, n/N (%), where N is the total number of patients with available data. p values are calculated by  $\chi^2$  test, Fisher's exact test, or Mann-Whitney U test. COPD=chronic obstructive pulmonary disease.

Data in bold indicated the statistical comparisons with significance.

Table 2: Demographics and clinical characteristics of patients with 1 or  $\geq$ 2 comorbidities.

Variables	1 comorbidity (n=269)	≥2 comorbidities (n=130)	P Value
Age (years)	58.2±13.1	66.2±12.2	<0.001
Incubation period (days)	3.2±3.1	4.0±5.2	0.124
Temperature on admission (□)	37.4±0.9	37.1±0.9	<0.001
Respiratory rate on admission (breath/min)	21.4±4.6	21.2±5	0.977
Heart rate (bit/minute)	90.2±14.6	87.2±13.7	0.134
Systolic pressure on admission (mmHg)	132.2±16.5	135.3±19.4	<0.001
Diastolic pressure on admission (mmHg)	81.7±12.5	79.5±12.9	0.350
Highest temperature (□)	38.2±3.0	38.4±0.8	0.424

Sex			0.430
Male	158/268 (59.0)	79/128 (61.7)	
Female	110/268 (41.0)	49/128 (38.3)	
Smoking status			<0.001
Never/unknown	234/269 (87.0)	118/130 (90.8)	
Former/current	35/269 (13.0)	12/130 (9.2)	
Symptoms			
Fever	241/263 (91.6)	108/125 (86.4)	0.126
Conjunctival congestion	3/222 (1.4)	0/109 (0)	0.374
Nasal congestion	5/213 (2.3)	9/107 (8.4)	0.046
Headache	34/220 (15.5)	20/106 (18.9)	0.589
Dry cough	195/258 (75.6)	82/124 (66.1)	0.088
Pharyngodynia	33/218 (15.1)	13/100 (13.0)	0.872
Productive cough	101/241 (41.9)	49/119 (41.2)	0.036
Fatigue	97/227 (42.7)	52/107 (48.6)	0.444
Hemoptysis	4/219 (1.8)	3/105 (2.9)	0.149
Shortness of breath	79/232 (34.1)	67/121 (55.4)	<0.001
Nausea/vomiting	23/236 (9.7)	13/110 (11.8)	<0.001
Diarrhea	11/229 (4.8)	7/107 (6.5)	0.359
Myalgia/arthralgia	45/227 (19.8)	15/104 (14.4)	0.457
Chill	25/222 (11.3)	9/105 (8.6)	0.400
Signs			
Throat congestion	4/216 (1.9)	1/97 (1)	0.868
Tonsil swelling	5/234 (2.1)	4/118 (3.4)	0.685

Enlargement of lymph nodes	1/232 (0.4)	0/116 (0)	0.441
Rash	0/231 (0)	1/115 (0.9)	0.249
Unconsciousness	3/240 (1.3)	6/118 (5.1)	0.002
Abnormal chest im	age		
Radiograph	63/269 (23.4)	27/130 (20.8)	<0.00
Computed tomography	200/269 (74.3)	96/130 (73.8)	0.283
Hubei			<0.00
Yes	120/269 (44.6)	93/130 (71.5)	
No	149/269 (55.4)	37/130 (28.5)	
Wuhan-contacte	d		0.003
Yes	229/269 (85.1)	122/130 (93.8)	
No	40/269 (14.9)	8/130 (6.2)	
Severity	79/269 (29.4)	52/130 (40.0)	<0.00
Composite endpoint	40/269 (14.9)	37/130 (28.5)	<0.002
Deaths	15/269 (5.6)	20/130 (15.4)	<0.002

Data are mean  $\pm$  standard deviation, n/N (%), where N is the total number of patients with available data. p values are calculated by  $\chi^2$  test, Fisher's exact test, or Mann-Whitney U test. COPD=chronic obstructive pulmonary disease.

Data in bold indicated the statistical comparisons with significance.

Table 3: Demographics and clinical characteristics of patients stratified by different comorbidities.

		COPD		Diabetes			Hypertension			Cardio	Cardiovascular disease			Cerebrovascular disease		
-	No	Yes (n=24)	P	No	Yes	P	No	Yes	P	No	Yes (n=59)	P	No	Yes (n=30)	P Back	
	(n=1566)		Value	(n=1460)	(n=130)	Value	(n=1321)	(n=269)	Value	(n=1531)		Value	(n=1560)		Value ava	
Age (year)	48.5±16.0	74.7±6.8	< 0.001	47.8±16.1	61.2±13.4	< 0.001	46.2±15.6	62.1±12.5	< 0.001	48.2±15.9	66.3±15.1	< 0.001	48.5±16.1	70.4±8.9	<0.001	
Incubation period (day)	3.6±4.2	4.5±3.2	0.331	3.6±4.1	3.8±5	0.619	3.6±4.2	3.6±4.1	0.958	3.7±4.2	3.3±3.7	0.564	3.6±4.2	3.8±3.4	0.867 er a	
Temperature on admission (□)	37.4±0.9	37.3±0.9	0.921	37.4±0.9	37.2±1	0.048	37.4±0.9	37.2±0.9	0.013	37.4±0.9	37.3±1	0.570	37.4±0.9	36.9±0.8	0.007	
Respiratory rate on admission (breath/min)	21.2±12.1	21.8±5.2	0.843	21.2±12.4	21.4±5.4	0.869	21.2±13.1	21.3±4.5	0.887	21.2±12.2	21.4±6.2	0.911	21.3±12.1	19.9±3.3	0.537	
Heart rate (bit/minute)	88.6±14.6	90.2±12.8	0.631	88.6±14.6	89.1±14.3	0.730	88.6±14.7	89±14.3	0.729	88.8±14.6	86.4±14.9	0.250	88.8±14.6	84.5±11.4	0.127 nternation	
Systolic pressure on admission (mmHg)	126±16.4	131±17.5	0.16	125.3±15.9	134.4±19.1	<0.001	123.9±15.2	135.4±18.2	<0.001	125.8±16.3	132.3±18.8	0.005	125.9±16.4	132.9±16	0.026 license	
Diastolic pressure on admission (mmHg)	79.6±25.7	77±11.9	0.640	79.4±26.4	80.9±13.2	0.551	79.2±27.7	81±12.5	0.298	79.6±25.9	78.4±13.6	0.746	79.6±25.8	77.4±9.6	0.655	
Highest temperature (□)	38.3±1.6	38.5±0.6	0.543	38.3±1.7	38.4±0.8	0.338	38.3±1.3	38.2±2.7	0.678	38.3±1.7	38.5±0.8	0.482	38.3±1.6	38.2±1	0.892	

Sex			0.011			0.711			0.635			0.500			0.039
Male	884/1554	20/24		828/1449	76/129		748/1312	156/266		868/1520	36/58		881/1548	23/30	
	(56.9)	(83.3)		(57.1)	(58.9)		(57)	(58.6)		(57.1)	(62.1)		(56.9)	(76.7)	
Female	670/1554	4/24 (16.7)		621/1449	53/129		564/1312	110/266		652/1520	22/58		667/1548	7/30 (23.3)	<u>s</u>
	(43.1)			(42.9)	(41.1)		(43)	(41.4)		(42.9)	(37.9)		(43.1)		made
Smoking status			0.232			0.002			0.430			0.298			0.152 available
Never/unknown	1458/1566	21/24		1368/1460	111/130		1232/1321	247/269		1426/1531	53/59		1453/1560	26/30	e und
	(93.1)	(87.5)		(93.7)	(85.4)		(93.3)	(91.8)		(93.1)	(89.8)		(93.1)	(86.7)	er a CC
Former/current	108/1566	3/24 (12.5)		92/1460	19/130		89/1321	22/269		105/1531	6/59 (10.2)		107/1560	4/30 (13.3)	<u>C</u> -BY-
	(6.9)			(6.3)	(14.6)		(6.7)	(8.2)		(6.9)			(6.9)		NC-NE
Symptoms															under a CC-BY-NC-ND 4.0 International license
Fever	1331/1513	20/23 (87)	0.751	1239/1412	112/124	0.473	1113/1273	238/263	0.177	1308/1482	43/54	0.051	1328/1507	23/29	0.150
	(88)			(87.7)	(90.3)		(87.4)	(90.5)		(88.3)	(79.6)		(88.1)	(79.3)	onal lic
Conjunctival congestion	10/1325	0/20 (0)	>0.999	9/1237	1/108 (0.9)	0.568	9/1120	1/225 (0.4)	>0.999	10/1299	0/46 (0)	>0.999	10/1320	0/25 (0)	>0.999
	(0.8)			(0.7)			(0.8)			(0.8)			(0.8)		
Nasal congestion	72/1281	1/18 (5.6)	>0.999	66/1195	7/104 (6.7)	0.655	62/1079	11/220 (5)	0.750	67/1253	6/46 (13)	0.040	73/1275	0/24 (0)	0.394
	(5.6)			(5.5)			(5.7)			(5.3)			(5.7)		

Headache	202/1309	3/19 (15.8)	>0.999	187/1225	18/103	0.317	166/1106	39/222	0.359	197/1283	8/45 (17.8)	0.674	197/1303	8/25 (32)	0.043
	(15.4)			(15.3)	(17.5)		(15)	(17.6)		(15.4)			(15.1)		
Dry cough	1038/1474	14/24	0.259	972/1378	80/120	0.405	854/1238	198/260	0.021	1018/1442	34/56	0.135	1035/1469	17/29	0.217
	(70.4)	(58.3)		(70.5)	(66.7)		(69)	(76.2)		(70.6)	(60.7)		(70.5)	(58.6)	
Pharyngodynia	189/1300	5/17 (29.4)	0.091	182/1219	12/98	0.555	165/1102	29/215	0.674	185/1272	9/45 (20)	0.288	192/1296	2/21 (9.5)	0.757
	(14.5)			(14.9)	(12.2)		(15)	(13.5)		(14.5)			(14.8)		
Productive cough	502/1400	11/24	0.391	462/1309	51/115	0.055	403/1178	110/246	0.002	499/1373	14/51	0.235	504/1397	9/27 (33.3)	0.842
	(35.9)	(45.8)		(35.3)	(44.3)		(34.2)	(44.7)		(36.3)	(27.5)		(36.1)		
Fatigue	573/1347	11/18	0.15	529/1257	55/108	0.085	488/1143	96/222	0.882	564/1318	20/47	>0.999	574/1344	10/21	0.663
	(42.5)	(61.1)		(42.1)	(50.9)		(42.7)	(43.2)		(42.8)	(42.6)		(42.7)	(47.6)	0.663
Hemoptysis	15/1296	1/19 (5.3)	0.209	12/1214 (1)	4/101 (4)	0.029	12/1096	4/219 (1.8)	0.323	15/1268	1/47 (2.1)	0.443	16/1292	0/23 (0)	
	(1.2)						(1.1)			(1.2)			(1.2)		
Shortness of breath	316/1371	15/23	< 0.001	277/1279	54/115 (47)	< 0.001	223/1154	108/240	< 0.001	310/1342	21/52	0.007	319/1366	12/28	0.023
	(23)	(65.2)		(21.7)			(19.3)	(45)		(23.1)	(40.4)		(23.4)	(42.9)	
Nausea/vomiting	77/1350	3/21 (14.3)	0.119	69/1264	11/107	0.051	55/1134	25/237	0.002	73/1321	7/50 (14)	0.023	79/1348	1/23 (4.3)	>0.999
	(5.7)			(5.5)	(10.3)		(4.9)	(10.5)		(5.5)			(5.9)		
Diarrhea	57/1338	0/21 (0)	>0.999	48/1255	9/104 (8.7)	0.035	46/1129	11/230	0.590	53/1313 (4)	4/46 (8.7)	0.123	57/1336	0/23 (0)	0.621

	(4.3)			(3.8)			(4.1)	(4.8)					(4.3)		
Myalgia/arthralgia	231/1320	3/18 (16.7)	>0.999	218/1234	16/104	0.687	188/1112	46/226	0.213	227/1294	7/44 (15.9)	>0.999	233/1317	1/21 (4.8)	0.1
	(17.5)			(17.7)	(15.4)		(16.9)	(20.4)		(17.5)			(17.7)		
Chill	159/1313	4/20 (20)	0.294	151/1230	12/103	1.000	140/1111	23/222	0.432	161/1290	2/43 (4.7)	0.156	162/1310	1/23 (4.3)	C
	(12.1)			(12.3)	(11.7)		(12.6)	(10.4)		(12.5)			(12.4)		
Signs															
Throat congestion	21/1269	0/17 (0)	>0.999	20/1189	1/97 (1)	>0.999	18/1075	3/211 (1.4)	>0.999	21/1245	0/41 (0)	>0.999	21/1266	0/20 (0)	>(
	(1.7)			(1.7)			(1.7)			(1.7)			(1.7)		
Tonsil swelling	31/1355	0/21 (0)	>0.999	28/1265	3/111 (2.7)	0.734	25/1133	6/243 (2.5)	0.811	29/1326	2/50 (4)	0.312	31/1348	0/28 (0)	>(
	(2.3)			(2.2)			(2.2)			(2.2)			(2.3)		
nlargement of lymph nodes	2/1355	0/20 (0)	>0.999	2/1267	0/108 (0)	>0.999	2/1135	0/240 (0)	>0.999	1/1325	1/50 (2)	0.071	2/1347	0/28 (0)	>(
	(0.1)			(0.2)			(0.2)			(0.1)			(0.1)		>(
Rash	3/1357	0/21 (0)	>0.999	2/1270	1/108 (0.9)	0.217	2/1141	1/237 (0.4)	0.433	3/1327	0/51 (0)	>0.999	3/1351	0/27 (0)	>(
	(0.2)			(0.2)			(0.2)			(0.2)			(0.2)		
Unconsciousness	18/1400	2/21 (9.5)	0.034	18/1309	2/112 (1.8)	0.668	12/1175 (1)	8/246 (3.3)	0.013	17/1371	3/50 (6)	0.031	19/1392	1/29 (3.4)	0
	(1.3)			(1.4)						(1.2)			(1.4)		

Radiograph	236/1566	7/24 (29.2)	0.079	218/1460	25/130	0.203	178/1321	65/269	< 0.001	231/1531	12/59	0.269	231/1560	12/30 (40)	0.001
	(15.1)			(14.9)	(19.2)		(13.5)	(24.2)		(15.1)	(20.3)		(14.8)		
Computed tomography	1113/1566	17/24	>0.999	1034/1460	96/130	0.545	926/1321	204/269	0.065	1090/1531	40/59	0.561	1111/1560	19/30	0.416
	(71.1)	(70.8)		(70.8)	(73.8)		(70.1)	(75.8)		(71.2)	(67.8)		(71.2)	(63.3)	<u>=</u>
Hubei			0.094			<0.001			< 0.001			< 0.001			<0.001 made
Yes	633/1566	14/24		568/1460	79/130		491/1321	156/269		609/1531	38/59		623/1560	24/30 (80)	availa
	(40.4)	(58.3)		(38.9)	(60.8)		(37.2)	(58)		(39.8)	(64.4)		(39.9)		ble und
No	933/1566	10/24		892/1460	51/130		830/1321	113/269		922/1531	21/59		937/1560	6/30 (20)	er a
	(59.6)	(41.7)		(61.1)	(39.2)		(62.8)	(42)		(60.2)	(35.6)		(60.1)		CC-BY
Wuhan-contacted			0.408			0.025			0.003			0.471			-made available under a CC-BY-NC-ND
Yes	1312/1566	22/24		1216/1460	118/130		1092/1321	242/269		1282/1531	52/59		1306/1560	28/30	4.0
	(83.8)	(91.7)		(83.3)	(90.8)		(82.7)	(90)		(83.7)	(88.1)		(83.7)	(93.3)	4.0 International license
No	254/1566	2/24 (8.3)		244/1460	12/130		229/1321	27/269 (10)		249/1531	7/59 (11.9)		254/1560	2/30 (6.7)	ional
	(16.2)			(16.7)	(9.2)		(17.3)			(16.3)			(16.3)		license
Severity	239/1566	15/24	< 0.001	209/1460	45/130	< 0.001	166/1321	88/269	< 0.001	234/1531	20/59	< 0.001	239/1560	15/30 (50)	<0.001
	(15.3)	(62.5)		(14.3)	(34.6)		(12.6)	(32.7)		(15.3)	(33.9)		(15.3)		,
Composite endpoint	119/1566	12/24 (50)	< 0.001	100/1460	31/130	<0.001	78/1321	53/269	< 0.001	118/1531	13/59 (22)	0.001	121/1560	10/30	<0.001

	(7.6)			(6.8)	(23.8)		(5.9)	(19.7)		(7.7)			(7.8)	(33.3)	
Deaths	44/1566	6/24 (25)	< 0.001	37/1460	13/130 (10)	< 0.001	22/1321	28/269	< 0.001	42/1531	8/59 (13.6)	< 0.001	44/1560	6/30 (20)	< 0.001
	(2.8)			(2.5)			(1.7)	(10.4)		(2.7)			(2.8)		
	Нера	atitis B infection	n		Malignancy		Chron	ic kidney disea	ise	Imr	nunodeficiency				
	No	Yes (n=24)	P	No	Yes	P	No	Yes	P	No	Yes (n=59)	P			
	(n=1566)		Value	(n=1460)	(n=130)	Value	(n=1321)	(n=269)	Value	(n=1531)		Value			
Age (year)	48.9±16.3	50.8±14.8	0.559	48.7±16.2	63.1±12.1	< 0.001	48.8±16.2	63.7±14	< 0.001	48.9±16.3	51±21.7	0.824			
Incubation period (day)	3.7±4.2	3±2.8	0.417	3.7±4.2	3.1±3.1	0.633	3.6±4.1	3.3±7.5	0.750	3.6±4.1	12.7±16.3	0.437			
Temperature on admission (□)	37.4±0.9	37.3±0.8	0.864	37.4±0.9	37.3±0.9	0.597	37.4±0.9	37.2±1	0.353	37.4±0.9	36.6±0.2	0.147			
Respiratory rate on admission	21.2±12.1	21.2±3	0.995	21.3±12.1	20.2±1.6	0.701	21.3±12.1	19±2.8	0.425	21.3±12	19±1	0.746			
(breath/min)															
Heart rate (bit/minute)	88.7±14.6	86.3±13.2	0.405	88.7±14.6	89.4±13.1	0.834	88.7±14.6	89.1±12.5	0.909	88.7±14.6	91±18.5	0.782			
Systolic pressure on admission	126.1±16.4	124.8±14.7	0.708	126±16.4	128.3±14.5	0.557	125.9±16.3	135.4±20.5	0.012	126.1±16.4	127.3±7.4	0.895			
(mmHg)															
Diastolic pressure on admission	79.6±25.7	78.3±13	0.817	79.5±25.7	81.2±8.8	0.784	79.5±25.7	79.8±14	0.967	79.5±25.6	84.7±15	0.728			
(mmHg)															

Highest temperature ( $\square$ )	38.3±1.5	37.6±4.4	0.457	38.3±1.6	38.5±0.9	0.516	38.3±1.6	38.5±0.5	0.586	38.3±1.6	38±0.5	0.789	
Sex			0.336			0.814			0.361			0.078	
Male	885/1550	19/28		893/1560	11/18		891/1559	13/19		904/1575	0/3 (0)		
	(57.1)	(67.9)		(57.2)	(61.1)		(57.2)	(68.4)		(57.4)			
Female	665/1550	9/28 (32.1)		667/1560	7/18 (38.9)		668/1559	6/19 (31.6)		671/1575	3/3 (100)		 
	(42.9)			(42.8)			(42.8)			(42.6)			
Smoking status			0.440			0.032			>0.999			0.195	
Never/unknown	1454/1562	25/28		1465/1572	14/18		1459/1569	20/21		1477/1587	2/3 (66.7)		
	(93.1)	(89.3)		(93.2)	(77.8)		(93)	(95.2)		(93.1)			
Former/current	108/1562	3/28 (10.7)		107/1572	4/18 (22.2)		110/1569	1/21 (4.8)		110/1587	1/3 (33.3)		 
	(6.9)			(6.8)			(7)			(6.9)			
Symptoms													
Fever	1326/1508	25/28	>0.999	1335/1519	16/17	0.711	1334/1516	17/20 (85)	0.725	1348/1533	3/3 (100)	>0.999	
	(87.9)	(89.3)		(87.9)	(94.1)		(88)			(87.9)			
Conjunctival congestion	9/1323	1/22 (4.5)	0.153	10/1330	0/15 (0)	>0.999	10/1328	0/17 (0)	>0.999	10/1343	0/2 (0)	>0.999	
	(0.7)			(0.8)			(0.8)			(0.7)			

Nasal congestion	73/1277	0/22 (0)	0.631	71/1285	2/14 (14.3)	0.184	73/1282	0/17 (0)	0.619	73/1297	0/2 (0)	>0.999	
	(5.7)			(5.5)			(5.7)			(5.6)			
Headache	202/1306	3/22 (13.6)	>0.999	203/1314	2/14 (14.3)	>0.999	203/1311	2/17 (11.8)	>0.999	205/1326	0/2 (0)	>0.999	-
	(15.5)			(15.4)			(15.5)			(15.5)			=
													<u>s</u>
Dry cough	1037/1472	15/26	0.193	1039/1481	13/17	0.791	1037/1479	15/19	0.614	1050/1495	2/3 (66.7)	>0.999	mad
	(70.4)	(57.7)		(70.2)	(76.5)		(70.1)	(78.9)		(70.2)			e av
													<u>ai</u>
Pharyngodynia	188/1294	6/23 (26.1)	0.134	193/1303	1/14 (7.1)	0.707	191/1300	3/17 (17.6)	0.728	193/1315	1/2 (50)	0.273	made available under a CC-BY-NC-ND 4.0 International license
	(14.5)			(14.8)			(14.7)			(14.7)			ınde
	· · ·			` ′			` '			` /			a a
Productive cough	508/1401	5/23 (21.7)	0.190	504/1408	9/16 (56.3)	0.115	505/1407	8/17 (47.1)	0.446	512/1421	1/3 (33.3)	>0.999	9
	(36.3)			(35.8)			(35.9)			(36)			84
	(30.3)			(33.0)			(33.7)			(50)			S.
Fatigue	570/1340	14/25 (56)	0.221	577/1349	7/16 (43.8)	>0.999	581/1350	3/15 (20)	0.113	583/1363	1/2 (50)	>0.999	D 4
	(42.5)			(42.8)			(43)			(42.8)			.0. Ir
	( /			(1210)			(12)			(1=10)			nterr
Hemoptysis	16/1293	0/22 (0)	>0.999	15/1299	1/16 (6.3)	0.179	16/1300	0/15 (0)	>0.999	16/1313	0/2 (0)	>0.999	atio
	(1.2)			(1.2)			(1.2)			(1.2)			na I
	` /			` ′			` '			` ′			icen
Shortness of breath	321/1370	10/24	0.05	323/1377	8/17 (47.1)	0.039	321/1375	10/19	0.006	330/1392	1/2 (50)	0.419	Se
	(23.4)	(41.7)		(23.5)			(23.3)	(52.6)		(23.7)			-
	(23.7)	(71.7)		(23.3)			(23.3)	(32.0)		(23.1)			
Nausea/vomiting	78/1349	2/22 (9.1)	0.371	78/1355	2/16 (12.5)	0.239	79/1351	1/20 (5)	>0.999	80/1369	0/2 (0)	>0.999	
2													

	(5.8)			(5.8)			(5.8)			(5.8)			
Diarrhea	55/1337	2/22 (9.1)	0.235	57/1343	0/16 (0)	>0.999	56/1339	1/20 (5)	0.578	56/1356	1/3 (33.3)	0.121	
	(4.1)			(4.2)			(4.2)			(4.1)			
Myalgia/arthralgia	232/1316	2/22 (9.1)	0.403	231/1322	3/16 (18.8)	0.75	233/1323	1/15 (6.7)	0.491	233/1336	1/2 (50)	0.319	
	(17.6)			(17.5)			(17.6)			(17.4)			2
Chill	161/1310	2/23 (8.7)	>0.999	162/1318	1/15 (6.7)	>0.999	161/1317	2/16 (12.5)	>0.999	163/1331	0/2 (0)	>0.999	
	(12.3)			(12.3)			(12.2)			(12.2)			2
Signs													a made a validation and the second
Throat congestion	21/1264	0/22 (0)	>0.999	20/1271	1/15 (6.7)	0.220	21/1271	0/15 (0)	>0.999	20/1284	1/2 (50)	0.032	
	(1.7)			(1.6)			(1.7)			(1.6)			(
Tonsil swelling	30/1353	1/23 (4.3)	0.410	30/1359	1/17 (5.9)	0.323	30/1356	1/20 (5)	0.368	31/1373	0/3 (0)	>0.999	
	(2.2)			(2.2)			(2.2)			(2.3)			
Enlargement of lymph nodes	2/1352	0/23 (0)	>0.999	2/1359	0/16 (0)	>0.999	2/1355	0/20 (0)	>0.999	2/1372	0/3 (0)	>0.999	
	(0.1)			(0.1)			(0.1)			(0.1)			T.O IIIGII augi ai liceli se
Rash	3/1355	0/23 (0)	>0.999	3/1361	0/17 (0)	>0.999	3/1360	0/18 (0)	>0.999	3/1376	0/2 (0)	>0.999	
	(0.2)			(0.2)			(0.2)			(0.2)			
Unconsciousness	19/1397	1/24 (4.2)	0.290	20/1404	0/17 (0)	>0.999	20/1401	0/20 (0)	>0.999	20/1418	0/3 (0)	>0.999	

														_
	(1.4)			(1.4)			(1.4)			(1.4)				
Abnormal chest image														_
Radiograph	240/1562	3/28 (10.7)	0.79	239/1572	4/18 (22.2)	0.504	240/1569	3/21 (14.3)	>0.999	243/1587	0/3 (0)	>0.999		_
	(15.4)			(15.2)			(15.3)			(15.3)				It is n
Computed tomography	1111/1562	19/28	0.679	1113/1572	17/18	0.033	1116/1569	14/21	0.634	1127/1587	3/3 (100)	0.561		nade a
	(71.1)	(67.9)		(70.8)	(94.4)		(71.1)	(66.7)		(71)				It is made available
Hubei			0.439			0.030			0.001			0.570		le under a
Yes	638/1562	9/28 (32.1)		635/1572	12/18		631/1569	16/21		645/1587	2/3 (66.7)			Ta CC
	(40.8)			(40.4)	(66.7)		(40.2)	(76.2)		(40.6)				BY-N
No	924/1562	19/28		937/1572	6/18 (33.3)		938/1569	5/21 (23.8)		942/1587	1/3 (33.3)			C-ND
	(59.2)	(67.9)		(59.6)			(59.8)			(59.4)				4.0 ln
Wuhan-contacted			0.436			0.097			>0.999			>0.999		CC-BY-NC-ND 4.0 International license
Yes	1312/1562	22/28		1316/1572	18/18 (100)		1316/1569	18/21		1331/1587	3/3 (100)			al lice
	(84)	(78.6)		(83.7)			(83.9)	(85.7)		(83.9)				nse .
No	250/1562	6/28 (21.4)		256/1572	0/18 (0)		253/1569	3/21 (14.3)		256/1587	0/3 (0)			
	(16)			(16.3)			(16.1)			(16.1)				

Severity	245/1562	9/28 (32.1)	0.032	245/1572	9/18 (50)	0.001	246/1569	8/21 (38.1)	0.012	253/1587	1/3 (33.3)	0.407
	(15.7)			(15.6)			(15.7)			(15.9)		
	120/15/2	2/20 /10 7)	0.400	104/1570	7/10 (20.0)	0.001	105/15/0	C/01 (00 C)	0.005	120/1507	1/0 (00.0)	0.227
Composite endpoint	128/1562	3/28 (10.7)	0.498	124/1572	7/18 (38.9)	< 0.001	125/1569	6/21 (28.6)	0.005	130/1587	1/3 (33.3)	0.227
	(8.2)			(7.9)			(8)			(8.2)		
Deaths	49/1562	1/28 (3.6)	0.594	47/1572 (3)	3/18 (16.7)	0.017	45/1569	5/21 (23.8)	< 0.001	50/1587	0/3 (0)	>0.999
	(3.1)						(2.9)			(3.2)		

Data are mean  $\pm$  standard deviation, n/N (%), where N is the total number of patients with available data. p values are calculated by  $\chi^2$  test, Fisher's exact test, or Mann-Whitney U test. COPD=chronic obstructive pulmonary disease.

## Figure legends

## Figure 1. Comparison of the time-dependent risk of reaching to the composite endpoints

Figure 1-A, The time-dependent risk of reaching to the composite endpoints between patients with (orange curve) or without any comorbidity (dark blue curve);


Figure 1-B, The time-dependent risk of reaching to the composite endpoints between patients without any comorbidity (orange curve), patients with a single comorbidity (dark blue curve), and patients with two or more comorbidities (green curve).

## Figure 2. Predictors of the composite endpoints in the proportional hazards model

Shown in the figure are the hazards ratio (HR) and the 95% confidence interval (95%CI) for the risk factors associated with the composite endpoints (admission to intensive care unit, invasive ventilation, or death). The comorbidities were classified according to the organ systems as well as the number.

The scale bar indicates the HR.

The model has been adjusted with age and smoking status



Features	Hazard I	Hazard Ratio (95%CI)					
Type of comorbidities	1						
COPD	H=	2.681	(1.424-5.048)	0.002			
Diabetes	<b>=</b> H	1.586	(1.028-2.449)	0.037			
Hypertension	<b>=</b> H	1.575	(1.069-2.322)	0.022			
Malignant tumor	<b>⊢=</b>	3.501	(1.604-7.643)	0.002			
Number of comorbidities							
1	=-1	1.789	(1.155-2.772)	0.009			
2 or more	H=1	2.592	(1.611-4.171)	< 0.001			
		- :					
	0 1	.0					
·				•			